Biblioteca Virtuale per la Salute – Piemonte – "Le biblioteche non si fanno…crescono" A. Birrell

Sfoglia per AUTORE
BOCCADORO M
Collezione AOU Città della Salute di Torino

Items : 162

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2025 Feb 18:JCO2401253. doi: 10.1200/JCO-24-01253.

2025
AOU Città della Salute di Torino

Kaiser MF; Sonneveld P; Cairns DA; Raab MS; San-Miguel Izquierdo J; Zhang R; Acosta J; Larocca A; Popat R; Li C; Baertsch MA; Brown SR; Lahuerta Palacios J; Gandhi AK; Macé S; Musto P; Yong K; Mai EK; Dubin F; Blade J; Capra A; Cook G; Bertsch U; Mateos MV; Boccadoro M; Jackson GH; Gutiérrez NC; Gay F; Weinhold N; et alii...

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2025 Apr;36(4):361-374. doi: 10.1016/j.annonc.2025.01.022. Epub 2025 Feb 7.

2025
AOU Città della Salute di Torino

Musto P; Engelhardt M; van de Donk NWCJ; Gay F; Terpos E; Einsele H; Fernández de Larrea C; Sgherza N; Bolli N; Katodritou E; Gentile M; Royer B; Derudas D; Jelinek T; Zamagni E; Rosiñol L; Paiva B; Caers J; Kaiser M; Beksac M; Hájek R; Spencer A; Ludwig H; Cavo M; Bladé J; Moreau P; Mateos MV; San-Miguel JF; Dimopoulos MA; et alii...

A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. in Haematologica / Haematologica. 2024 May 1;109(5):1525-1534. doi: 10.3324/haematol.2023.284023.

2024
AOU Città della Salute di Torino

Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M;

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. in Leukemia / Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7.

2024
AOU Città della Salute di Torino

Hillengass J; Dimopoulos MA; Scheid C; Boccadoro M; Müller-Tidow C; Graeven U; Hänel M; von Metzler I; van der Holt B; Reimer P; Fenk R; Besemer B; Dürig J; Blau IW; Beksac M; Brossart P; Mancuso K; Pantani L; Munder M; Raab MS; Zweegman S; Salwender HJ; Hielscher T; Bertsch U; Mai EK; Weisel KC; Cavo M; Sonneveld P; Goldschmidt H; et alii...

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. in Blood cancer journal / Blood Cancer J. 2024 Jun 7;14(1):94. doi: 10.1038/s41408-024-01075-x.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bruno B; Zamagni E; Stefanoni P; Palmieri S; Liberati AM; Monaco F; Annibali O; Galieni P; Garzia M; Olivero M; Rogers J; Ruggeri M; Pescosta N; Pisani F; Tosi P; Pascarella A; Pietrantuono G; Arigoni M; De Sabbata G; Bertamini L; Belotti A; Rota-Scalabrini D; D'Agostino M; Calogero RA; Boccadoro M; Musto P; Gay F;

Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy. in EJHaem / EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun.

2024
AOU Città della Salute di Torino

Derudas D; Gamberi B; Musto P; De Stefano V; Renzo ND; Conticello C; Antonioli E; Bringhen S; Belotti A; Zambello R; Tacchetti P; Musso M; Piciocchi A; Della Pepa R; Corvatta L; Petrucci MT; Fazio F; Boccadoro M; Offidani M; Morè S;

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma. in Blood cancer journal / Blood Cancer J. 2024 Jul 19;14(1):117. doi: 10.1038/s41408-024-01096-6.

2024
AOU Città della Salute di Torino

Ziccheddu B; Giannotta C; D'Agostino M; Bertuglia G; Saraci E; Oliva S; Genuardi E; Papadimitriou M; Diamond B; Corradini P; Coffey D; Landgren O; Bolli N; Bruno B; Boccadoro M; Massaia M; Maura F; Larocca A;

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.

2024
AOU Città della Salute di Torino

Moreau P; Bladé J; Rodriguez-Otero P; Carson R; de Boer CJ; Sitthi-Amorn A; Vanquickelberghe V; van Brummelen EMJ; Vieyra D; Wang J; Liu Y; Ahmadi T; Lonergan S; Jurczyszyn A; Hajek R; Spencer A; Einsele H; Vangsted A; Silzle T; Roeloffzen W; Delforge M; Rosiñol L; Sureda Balari A; Schjesvold F; Katodritou E; van de Donk NWCJ; Nijhof IS; Mina R; Gay F; et alii...

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. in Future oncology (London, England) / Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.

2024
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; et alii...

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.

2023
AOU Città della Salute di Torino

Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P;

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AOU Città della Salute di Torino

Benjamin R; Hájek R; Zweegman S; Silkjaer T; Caers J; Mancuso K; Tacchetti P; Razawy W; Grasso M; Giaccone L; Offidani M; Lund T; van der Velden VHJ; Pour L; Gadisseur A; Pietrantuono G; Broijl A; Roeloffzen WWH; Wu KL; Schjesvold F; van der Holt B; Minnema MC; van de Donk NWCJ; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P;

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. in The Lancet. Oncology / Lancet Oncol. 2023 Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6.

2023
AOU Città della Salute di Torino

Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P; et alii...

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.

2023
AOU Città della Salute di Torino

Terpos E; Musto P; Engelhardt M; Delforge M; Cook G; Gay F; van de Donk NWCJ; Ntanasis-Stathopoulos I; Vangsted AJ; Driessen C; Schjesvold F; Cerchione C; Zweegman S; Hajek R; Moreau P; Einsele H; San-Miguel J; Boccadoro M; Dimopoulos MA; Sonneveld P; Ludwig H;

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F;

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Zamagni E; Oliva S; Gay F; Capra A; Rota-Scalabrini D; D'Agostino M; Belotti A; Galli M; Racca M; Zambello R; Gamberi B; Albano D; Bertamini L; Versari A; Grasso M; Sgherza N; Priola C; Fioritoni F; Patriarca F; De Cicco G; Villanova T; Pascarella A; Zucchetta P; Tacchetti P; Fanti S; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino

Grasso M; Zamagni E; Fioritoni F; Ballanti S; Cea M; Pescosta N; Pavone V; Ronconi S; Vincelli ID; Oddolo D; Capra A; Bertamini L; Cellini C; Gozzetti A; De Rosa L; Giuliani N; Aquino S; de Fabritiis P; Gamberi B; Palmas A; Rota-Scalabrini D; Paris L; Musto P; Mina R; Belotti A; Boccadoro M; Gay F;

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6.

2022
AOU Alessandria
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Belotti A; Tacchetti P; Fazio F; Zambello R; Luppi M; Liberati AM; Palmieri S; Annibali O; Monaco F; Galieni P; Pisani F; Capra A; Gilestro M; Curci P; Pascarella A; Tosi P; De Sabbata G; Pietrantuono G; Gentile M; Ledda A; Paris L; Morè S; Corradini P; Rota-Scalabrini D; Oliva S; Bertamini L; et alii...

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Sep;33(9):988. doi: 10.1016/j.annonc.2022.05.004. Epub 2022 Jul 6.

2022
AOU Città della Salute di Torino

Boccadoro M; Einsele H; Facon T; Goldschmidt H; Cavo M; Schjesvold F; Cook G; Delforge M; Hájek R; Zweegman S; Mateos MV; Terpos E; Moreau P; Dimopoulos MA; San-Miguel J; Sonneveld P; Mey U;

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.

2022
AOU Città della Salute di Torino

Cook G; Larocca A; Hernández Rivas JM; Goldschmidt H; Kaiser MF; Cavo M; Zweegman S; Gay F; Dürig J; Mai EK; Capra A; Castellani G; Bonello F; van der Holt B; Salwender H; Bladé Creixenti J; Rocchi S; van de Donk NWCJ; Jackson G; Dall'Olio D; Mateos MV; Zamagni E; Waage A; Bertsch U; Lahuerta JJ; Wester R; Cairns DA; D'Agostino M; San-Miguel JF; et alii...

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. in Hematological oncology / Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1.

2022
AOU Città della Salute di Torino

Zamagni E; Bringhen S; Consoli U; Frigeri F; Pompa A; Tripepi G; Gamberi B; Gagliardi A; Gangemi D; Ballanti S; Martino M; Stocchi R; Cupelli L; Bonalumi A; Sgherza N; Vincelli D; Botta C; Mimmi S; Iaccino E; Vigna E; Mendicino F; Curci P; Uccello G; Criscuolo C; Belotti A; Cerchione C; Cascavilla N; Palumbo G; Pietrantuono G; et alii...

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. in HemaSphere / Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.

2022
AOU Città della Salute di Torino

Sonneveld P; Zweegman S; Cavo M; Nasserinejad K; Broijl A; Troia R; Pour L; Croockewit S; Corradini P; Patriarca F; Wu K; Droogendijk J; Bos G; Hajek R; Teresa Petrucci M; Ypma P; Zojer N; Minnema MC; Boccadoro M;

Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. in Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis / Amyloid. 2022 Mar;29(1):1-7. doi: 10.1080/13506129.2021.2002841. Epub 2021 Nov 16.

2022
AOU Città della Salute di Torino

Mollee P; Landau H; Hegenbart U; Kastritis E; Gertz M; Boccadoro M; Sanchorawala V; Wechalekar A; Palladini G;

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. in European journal of haematology / Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 2021 Nov 9.

2022
AOU Città della Salute di Torino

Musso M; De Stefano V; Musto P; Rizzello I; Barone M; Farina G; Reddiconto G; Cangialosi C; Pia Falcone A; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Bruzzese A; Botta C; Vigna E; Antonia Martino E; Mele G; Donatella Vincelli I; Tacchetti P; Catalano L; Ria R; Rossi E; Derudas D; Galli M; et alii...

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):117. doi: 10.1016/j.annonc.2021.10.001. Epub 2021 Nov 29.

2022
AOU Città della Salute di Torino

Boccadoro M; Einsele H; Facon T; Goldschmidt H; Cavo M; Schjesvold F; Delforge M; Hájek R; Cook G; Zweegman S; Mateos MV; Terpos E; Moreau P; Dimopoulos MA; San-Miguel J; Sonneveld P; Mey U;

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. in Bone marrow transplantation / Bone Marrow Transplant. 2022 Feb;57(2):312-314. doi: 10.1038/s41409-021-01541-1. Epub 2021 Nov 30.

2022
AOU Città della Salute di Torino

Tassi V; Evangelista A; Francisci T; Cattel F; Leone S; Bringhen S; Cavallo F; Ferrero D; Massaia M; Lia G; Omedè P; Redoglia V; Cerrano M; Scaldaferri M; Londono JS; Brunello L; Giaccone L; Boccadoro M; Bruno B;

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials. in Frontiers in oncology / Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022.

2022
AOU Città della Salute di Torino

De Stefano V; Musto P; Gamberi B; Curci P; Mimmi S; Rizzello I; Iaccino E; Barone M; Farina G; Reddiconto G; Cangialosi C; Falcone AP; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Botta C; Mendicino F; Bruzzese A; Martino EA; Vigna E; Mele G; Vincelli ID; Tacchetti P; Catalano L; et alii...

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. in Cancer / Cancer. 2021 Sep 15;127(18):3413-3421. doi: 10.1002/cncr.33647. Epub 2021 Jun 28.

2021
AOU Città della Salute di Torino

Einsele H; Palumbo A; Straka C; Corradini P; Wäsch R; Gentili S; Schub N; Spada S; Pönisch W; Aquino S; Patriarca F; Montefusco V; Salvini M; Engelhardt M; Offidani M; Günther A; Gay F; Boccadoro M; Sonneveld P; Gramatzki M;

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. in Annals of hematology / Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.

2021
AOU Città della Salute di Torino

Zonder J; Boccadoro M; Thompson M; Weisel K; Berdeja J; Lee HC; Leleu X; Huang H; Stull DM; Cherepanov D; Terpos E; Hajek R; Romanus D; Palumbo A; Abonour R; Usmani S; Morgan G; Costello C; Rifkin R; Davies F; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A;

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14.

2021
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; et alii...

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. in Haematologica / Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.

2021
AOU Città della Salute di Torino

Engelhardt M; Musto P; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS;

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.

2021
AOU Città della Salute di Torino

Boccadoro M; Einsele H; Facon T; Goldschmidt H; Cavo M; Schjesvold F; Delforge M; Hájek R; Cook G; Zweegman S; Mateos MV; Terpos E; Moreau P; Dimopoulos MA; San-Miguel J; Sonneveld P; Mey U;

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.

2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Targeting HIF-1? Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. in Cancers / Cancers (Basel). 2021 Jun 9;13(12):2883. doi: 10.3390/cancers13122883.

2021
AOU Città della Salute di Torino

Vitale C; Griggio V; Riganti C; Todaro M; Kopecka J; Jones R; Salvetti C; Boccellato E; Perutelli F; Voena C; Godio L; Boccadoro M; Coscia M;

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. in Blood / Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507.

2021
AOU Alessandria
AOU Città della Salute di Torino

Tacchetti P; Corradini P; Caravita di Toritto T; Patriarca F; Pompa A; Monaco F; Cellini C; Rota-Scalabrini D; Antonioli E; Bernardini A; Giuliani N; Galli M; Marasca R; Tosi P; Benevolo G; Capra A; Cascavilla N; Offidani M; Gaidano G; D'Agostino M; Bonello F; Larocca A; Boccadoro M; Bringhen S;

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. in Blood cancer journal / Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0.

2021
AOU Città della Salute di Torino

Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P;

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.

2021
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Boccadoro M; Coscia M; Mauro FR; Foà R; Gaidano G; Tedeschi A; Scarfò L; Cuneo A; Orsucci L; Trentin L; De Paoli L; Reda G; Montalbano MC; Perutelli F; Gentile M; Boccellato E; Pennese E; Marchetti M; Laurenti L; Rivela P; Rigolin GM; Murru R; Vassallo F; Cassin R; Visentin A; Schiattone L; Zamprogna G; Porrazzo M; Griggio V; et alii...

Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2021 Jul 1;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29.

2021
AOU Città della Salute di Torino

Hájek R; Spencer A; Nagler A; Gaidano G; Belotti A; Benevolo G; Patriarca F; Mina R; Ruggeri M; Cascavilla N; de Fabritiis P; Mannina D; Liberati AM; Romano A; Capra A; Corradini P; Offidani M; Petrucci MT; Bertamini L; Zaccaria GM; Sonneveld P; Musto P; Boccadoro M; Gay F;

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. in Haematologica / Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.

2021
AOU Città della Salute di Torino

Gentile M; Specchia G; Derudas D; Galli M; Botta C; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Attingenti E; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Musto P; Capalbo S; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; et alii...

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2021 Jan;35(1):31-44. doi: 10.1038/s41375-020-01016-0. Epub 2020 Aug 19.

2021
AOU Città della Salute di Torino

van de Donk N; Leleu X; Engelhardt M; Garderet L; Jackson G; Weisel K; Caers J; Delforge M; Mateos MV; Einsele H; Mohty M; Zojer N; Terpos E; Avet-Loiseau H; Gay F; Dimopoulos MA; Hajek R; Facon T; Driessen C; Zweegman S; Pawlyn C; San-Miguel J; Cavo M; Moreau P; Boccadoro M; Ludwig H; Goldschmidt H; Beksac M; Nijhof I; et alii...

Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e21-e24. doi: 10.1016/j.clml.2020.08.019. Epub 2020 Sep 1

2021
AOU Città della Salute di Torino

Zamagni E; Boccadoro M; Gay F; Bonello F; Mina R;

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. in HemaSphere / Hemasphere. 2021 Feb 3;5(2):e528. doi: 10.1097/HS9.0000000000000528. eCollection 2021 Feb.

2021
AOU Città della Salute di Torino

Dimopoulos MA; Moreau P; Terpos E; Mateos MV; Zweegman S; Cook G; Delforge M; Hájek R; Schjesvold F; Cavo M; Goldschmidt H; Facon T; Einsele H; Boccadoro M; San-Miguel J; Sonneveld P; Mey U;

A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. in Annals of hematology / Ann Hematol. 2021 Feb;100(2):437-443. doi: 10.1007/s00277-020-04384-w. Epub 2021 Jan 3.

2021
AOU Città della Salute di Torino

Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P;

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. in The Lancet. Haematology / Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.

2021
AOU Città della Salute di Torino

Ludwig H; Sonneveld P; Facon T; San-Miguel J; Avet-Loiseau H; Mohty M; Mateos MV; Moreau P; Cavo M; Pawlyn C; Zweegman S; Engelhardt M; Driessen C; Cook G; Dimopoulos MA; Gay F; Einsele H; Delforge M; Caers J; Weisel K; Jackson G; Garderet L; van de Donk N; Leleu X; Goldschmidt H; Beksac M; Nijhof I; Schreder M; Abildgaard N; et alii...

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. in Haematologica / Haematologica. 2021 Aug 1;106(8):2054-2065. doi: 10.3324/haematol.2020.276402.

2021
AOU Città della Salute di Torino

Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M;

Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):293-303. doi: 10.1002/hon.2864. Epub 2021 Mar 31.

2021
AOU Alessandria
AOU Città della Salute di Torino

Ladetto M; Splinter E; van Min M; Federico M; Boccadoro M; Luminari S; Vitolo U; Cortelazzo S; Zaccaria GM; Yilmaz M; Lo Schirico M; Saraci E; Clerico M; Ragaini S; Dogliotti I; Grimaldi D; Alessandria B; Cavallo F; Drandi D; Ferrante M; Mantoan B; Klous P; Genuardi E; Ferrero S;

Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? in Leukemia research / Leuk Res. 2021 Aug;107:106592. doi: 10.1016/j.leukres.2021.106592. Epub 2021 Apr 24.

2021
AOU Città della Salute di Torino

Boccadoro M; Gay F; Oliva S; Bonello F; Ferrero D;

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. in Blood cancer journal / Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.

2021
ASL Torino 4
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Hájek R; Sonneveld P; Boccadoro M; Musto P; Guglielmelli T; Di Raimondo F; Corradini P; Aitoro G; Benevolo G; Giuliani N; Patriarca F; Bonello F; de Fabritiis P; Innao V; Zambello R; Cascavilla N; Derudas D; Capra A; Petrucci MT; Gaidano G; Offidani M; Liberati AM; Larocca A; D'Agostino M; Bringhen S;

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. in Haematologica / Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428.

2021
AOU Città della Salute di Torino

Mina R; Bonello F; Petrucci MT; Liberati AM; Conticello C; Ballanti S; Musto P; Olivieri A; Benevolo G; Capra A; Gilestro M; Galieni P; Cavo M; Siniscalchi A; Palumbo A; Montefusco V; Gaidano G; Omedé P; Boccadoro M; Bringhen S;

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2020 Sep 15;26(18):4832-4841. doi: 10.1158/1078-0432.CCR-20-0951. Epub 2020 Jul 2.

2020
AOU Città della Salute di Torino

D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; Gambella M; Bringhen S; Larocca A; Boccadoro M; Bolli N; Maura F; Gay F; D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; et alii...

New drugs in early development for treating multiple myeloma: all that glitters is not gold. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2020 Sep;29(9):989-1004. doi: 10.1080/13543784.2020.1772753. Epub 2020 S

2020
AOU Città della Salute di Torino

Bertamini L; Bonello F; Boccadoro M; Bringhen S;

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. in Annals of hematology / Ann Hematol. 2020 Sep;99(9):2197-2199. doi: 10.1007/s00277-020-04180-6. Epub 2020 Jul 13.

2020
AOU Città della Salute di Torino

Apolito V; Giaccone L; Ferrero S; Larocca A; Cavallo F; Coscia M; Beggiato E; Butera S; Martella F; Dainese C; Cetani G; Scaldaferri M; Cattel F; Boccadoro M; Ferrero D; Bruno B; Cerrano M; Apolito V; Giaccone L; Ferrero S; Larocca A; Cavallo F; Coscia M; Beggiato E; Butera S; Martella F; Dainese C; Cetani G; Scaldaferri M; et alii...

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. in Cancers / Cancers (Basel). 2020 Oct 24;12(11):3106. doi: 10.3390/cancers12113106.

2020
AOU Città della Salute di Torino

Bonello F; Boccadoro M; Larocca A;

Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. in British journal of haematology / Br J Haematol. 2020 Oct;191(1):e28-e32. doi: 10.1111/bjh.16960. Epub 2020 Jul 19.

2020
AOU Città della Salute di Torino

Cerrano M; Castella B; Lia G; Olivi M; Faraci DG; Butera S; Martella F; Scaldaferri M; Cattel F; Boccadoro M; Massaia M; Ferrero D; Bruno B; Giaccone L; Cerrano M; Castella B; Lia G; Olivi M; Faraci DG; Butera S; Martella F; Scaldaferri M; Cattel F; Boccadoro M; Massaia M; Ferrero D; Bruno B; Giaccone L;

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. in International journal of molecular sciences / Int J Mol Sci. 2020 Nov 1;21(21):8192. doi: 10.3390/ijms21218192.

2020
AOU Città della Salute di Torino

D'Agostino M; Innorcia S; Boccadoro M; Bringhen S;

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Asti
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Romano A; Sonneveld P; Ria R; Musto P; Liberati AM; Offidani M; Giuliani N; Marchetti M; Mosca-Siez ML; de Fabritiis P; Gobbi M; Ballanti S; Cellini C; Grasso M; Monaco F; Ronconi S; Pescosta N; Di Lullo G; Capra A; Belotti A; Petrucci MT; Boccadoro M; Zambello R; Mina R;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino

Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. in Haematologica / Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.

2020
ASL Torino 4
AOU Città della Salute di Torino

Boccadoro M; Larocca A; Falco P; Hájek R; Palumbo A; Marasca R; Cellini C; Petrucci MT; Tosi P; Gentile M; Baldini L; Santoro A; Aquino S; Poggiu M; Pavone V; Gazzera G; De Rosa L; Grasso M; Rota-Scalabrini D; Pezzatti S; Spada S; Ballanti S; Pescosta N; Paris L; D'Agostino M; Bringhen S;

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. in Cancers / Cancers (Basel). 2020 Jan 23;12(2):282. doi: 10.3390/cancers12020282.

2020
AOU Città della Salute di Torino

Vitale C; Montalbano MC; Salvetti C; Boccellato E; Griggio V; Boccadoro M; Coscia M;

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. in Haematologica / Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20.

2020
AOU Città della Salute di Torino
AOU Novara

Corradini P; Cavo M; Offidani M; Liberati AM; Sonneveld P; Hajek R; Nagler A; Ben-Yehuda D; Cascavilla N; Nozzoli C; Ballanti S; Galieni P; Patriarca F; Musto P; Musolino C; Ribolla R; De Paoli L; Di Raimondo F; Spada S; Boccadoro M; Gay F; Montefusco V;

Droplet Digital PCR Assay for MYD88 (L265P) : Clinical Applications in Waldenström Macroglobulinemia. in HemaSphere / Hemasphere. 2020 Jan 3;4(1):e324. doi: 10.1097/HS9.0000000000000324. eCollection 2020 Feb.

2020
AOU Alessandria
AOU Città della Salute di Torino

Boccadoro M; Ladetto M; Cavallo F; Omedè P; Benevolo G; Bertuzzo D; Ferrero B; Zamò A; Dogliotti I; Ferrante M; Lo Schirico M; Drandi D; Ferrero S;

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020.

2020
AO Cuneo
AOU Città della Salute di Torino

Bringhen S; Boccadoro M; Castellino A; Celeghini I; Grasso M; D'Agostino M; Bonello F;

Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. J. Clin. Med. 2020, 9, 2142. in Journal of clinical medicine / J Clin Med. 2020 Aug 13;9(8):2630. doi: 10.3390/jcm9082630.

2020
AOU Città della Salute di Torino

Mina R; Oliva S; Boccadoro M;

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2020 Aug;34(8):2000-2011. doi: 10.1038/s41375-020-0876-z. Epub 2020 May 22.

2020
AOU Città della Salute di Torino

Terpos E; Engelhardt M; Cook G; Gay F; Mateos MV; Ntanasis-Stathopoulos I; van de Donk NWCJ; Avet-Loiseau H; Hajek R; Vangsted AJ; Ludwig H; Zweegman S; Moreau P; Einsele H; Boccadoro M; San Miguel J; Dimopoulos MA; Sonneveld P; Terpos E; Engelhardt M; Cook G; Gay F; Mateos MV; Ntanasis-Stathopoulos I; van de Donk NWCJ; Avet-Loiseau H; Hajek R; Vangsted AJ; Ludwig H; et alii...

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. in Blood cancer journal / Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.

2020
AOU Città della Salute di Torino

Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omedé P; Boise LH; Roussou M; Giuliani N; Oliva S; Offidani M; Belotti A; Jaye DL; De Paoli L; Terpos E; Lonial S; Boccadoro M; Nooka AK; Dimopoulos MA;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. in Haematologica / Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27.

2020
AOU Città della Salute di Torino

Palumbo A; De Paoli L; Romano A; Zambello R; Falcone AP; Giuliani N; Paris L; Fraticelli V; Amico V; Musto P; Bernardini A; Cangiolosi C; Innao V; Oddolo D; Benevolo G; Spada S; Evangelista A; Patriarca F; Ledda A; Liberati AM; Offidani M; Mina R; Larocca A; Montefusco V; Hájek R; Boccadoro M; Bringhen S;

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. in Frontiers in immunology / Front Immunol. 2020 Nov 18;11:594556. doi: 10.3389/fimmu.2020.594556. eCollection 2020.

2020
AOU Città della Salute di Torino

Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M; Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M;

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. in Frontiers in oncology / Front Oncol. 2020 Jan 31;10:1. doi: 10.3389/fonc.2020.00001. eCollection 2020.

2020
AOU Città della Salute di Torino

Oliva S; D'Agostino M; Boccadoro M; Larocca A;

Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. in JCO clinical cancer informatics / JCO Clin Cancer Inform. 2019 Oct;3:1-15. doi: 10.1200/CCI.19.00049.

2019
AOU Alessandria
AOU Città della Salute di Torino

Omedè P; Ferreri A; Molinari AL; Ballerini F; Arcaini L; Lo Schirico M; Castagneri C; Barbero D; Sandrone R; Evangelista A; Genuardi E; Ghislieri M; Rosati S; Zaccaria GM; Ferrero S; Zamò A; Balestra G; Boccadoro M; Cortelazzo S; Ladetto M;

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. in Cancers / Cancers (Basel). 2019 Nov 5;11(11):1735. doi: 10.3390/cancers11111735.

2019
AOU Città della Salute di Torino

Bonello F; Pulini S; Ballanti S; Gentile M; Spada S; Annibali O; Omedé P; Ronconi S; Cangialosi C; Podda L; Palmas A; Malfitano A; Rivoli G; Belotti A; Ciambelli F; Vincelli ID; Cafro AM; Innao V; Palumbo A; Sonneveld P; Spencer A; Hájek R; Boccadoro M; Gay F;

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. in Cancer / Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.

2019
AOU Città della Salute di Torino

Sonneveld P; Cavo M; Palumbo A; Rocci A; Liberati AM; Offidani M; Gamberi B; Troia R; Bernardini A; Conticello C; Larocca A; Grammatico S; Saraci E; Gilestro M; Muccio VE; Spada S; Omedé P; Gambella M; Boccadoro M; Oliva S; Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; et alii...

Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives. in Frontiers in bioscience (Landmark edition) / Front Biosci (Landmark Ed). 2019 Jun 1;24(7):1284-1315. doi: 10.2741/4780.

2019
AOU Città della Salute di Torino

Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B;

Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. in Current hematologic malignancy reports / Curr Hematol Malig Rep. 2019 Jun;14(3):187-196. doi: 10.1007/s11899-019-00507-x.

2019
AOU Città della Salute di Torino

Offidani M; Boccadoro M; Di Raimondo F; Petrucci MT; Tosi P; Cavo M;

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. in Journal of internal medicine / J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

2019
AOU Città della Salute di Torino

Boccadoro M; Dimopoulos MA; Caers J; Gramatzki M; Auner HW; Ludwig H; Driessen C; Cavo M; Goldschmidt H; Terpos E; Zweegman S; Offidani M; Larocca A; Gay F; Wäsch R; Ferri C; D'Agostino M; Milan A; Bringhen S; Einsele H; Sonneveld P; Engelhardt M;

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. in Journal of hematology & oncology / J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ria R; Boccadoro M; Vacca A; Dammacco F; Petrucci MT; Musto P; Montefusco V; Rizzo M; Falcone AP; Grasso M; Gottardi D; Leonardi G; Baldini L; Benevolo G; Callea V; Patriarca F; Guglielmelli T; Nozzoli C; Larocca A; Offidani M; De Paoli L; Martino E; Bringhen S; Palumbo A; Omedè P; Giuliani N; Saltarella I; Terragna C; Morabito F; et alii...

Insights on Multiple Myeloma Treatment Strategies. in HemaSphere / Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb.

2019
AOU Città della Salute di Torino

Plesner T; San-Miguel JF; O'Dwyer M; Mendeleeva L; Masszi T; Leiba M; Jamroziak K; Hansson M; Hájek R; Goldschmidt H; Geraldes C; Facon T; Dimopoulos MA; Delforge M; Cavo M; Boccadoro M; Bladé J; Beksac M; Bazarbachi A; Ludwig H; Mateos MV; Straka C; van de Donk NWCJ; Yong K; Zver S; Moreau P; Sonneveld P; Mateos MV; Ludwig H; et alii...

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). in Annals of hematology / Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23.

2019
AOU Città della Salute di Torino

Caravita T; Reddiconto G; Fragasso A; Di Renzo N; Genuardi M; Bringhen S; Mansueto G; D'Arena G; Pietrantuono G; Villani O; Gagliardi A; Mastrullo L; Catalano L; Salvatore D; Ria R; Conticello C; Di Raimondo F; Cesini L; Petrucci MT; Falcone A; Cascavilla N; Simeon V; Musto P; Scapicchio D; Marziano G; Boccadoro M; Mangiacavalli S; Corso A; Musto P; et alii...

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. in Cancers / Cancers (Basel). 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015.

2019
AOU Città della Salute di Torino

Bonello F; Mina R; Boccadoro M; Gay F;

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. in Cancers / Cancers (Basel). 2019 Dec 13;11(12):2015. doi: 10.3390/cancers11122015.

2019
AOU Città della Salute di Torino

D'Agostino M; Bertamini L; Oliva S; Boccadoro M; Gay F;

FLAI induction regimen in elderly patients with acute myeloid leukemia. in Leukemia & lymphoma / Leuk Lymphoma. 2019 Dec;60(13):3339-3340. doi: 10.1080/10428194.2019.1620943. Epub 2019 Jun 4.

2019
AOU Città della Salute di Torino

Bruno B; Audisio E; Boccadoro M; Zannier ME; D'Ardia S; Crisà E; Dubbini MV; Candoni A; Cerrano M; Ferrero D;

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. in Haematologica / Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.

2019
AOU Città della Salute di Torino

Palumbo A; Di Raimondo F; Montefusco V; Di Toritto TC; Cavo M; Galieni P; Ponticelli E; Benevolo G; Spada S; Offidani M; Musto P; Ballanti S; Gaidano G; Petrucci MT; Mina R; Bringhen S; Boccadoro M; Larocca A;

Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. in Current medicinal chemistry / Curr Med Chem. 2019;26(32):5968-5981. doi: 10.2174/0929867325666180514114806.

2019
AOU Città della Salute di Torino

D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F;

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. in British journal of haematology / Br J Haematol. 2018 Sep;182(5):701-704. doi: 10.1111/bjh.15450. Epub 2018 Jul 9.

2018
ASL Asti
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Ferrero D; Boccadoro M; Mezzabotta M; Marchetti M; Lanzarone G; Cerrano M; Frairia C; Pugliese N; Beggiato E; Martinelli V; Palumbo GA; Elli EM; Cilloni D; Crisà E;

Determining treatment intensity in elderly patients with multiple myeloma. in Expert review of anticancer therapy / Expert Rev Anticancer Ther. 2018 Sep;18(9):917-930. doi: 10.1080/14737140.2018.1496823. Epub 2018 Ju